Bayer Aktiengesellschaft is a global life science company operating in the health care and agriculture sectors. The company is organized into three main business segments: Pharmaceuticals, Consumer Health, and Crop Science. In Pharmaceuticals, Bayer researches, develops, manufactures, and markets products for the prevention, diagnosis, and treatment of diseases. The Consumer Health segment provides over-the-counter self-care products to support consumer well-being. The Crop Science segment offers seeds and crop protection solutions to support agricultural production. Bayer serves patients, consumers, and farmers globally, with a strong presence in markets worldwide. The company’s portfolio includes well-known brands across its segments, and it manages specific legal risks associated with its Roundup product in the United States. Bayer combines scientific innovation with digital technologies to address challenges in health and nutrition.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Drug Manufacturers - General Homepage bayer.com
Sector Healthcare IR page bayer.com/en/investors
Tags
pharmaceuticals, consumer health, crop science, seeds, crop protection, over-the-counter, disease treatment, agriculture, life sciences, Roundup
Press page —

Metrics

Valuation  
Market cap € 49.691B
Market cap (USD) $ 54.918B
P/E -34.41
PEG —
P/BV 2.00
P/S 1.09
P/OCF 8.38
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin -7.9%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock —
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -46.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Revenue 45.575B 46.606B 47.637B 50.739B 44.081B 41.4B 43.545B 39.586B 35.015B 46.769B 46.324B 42.239B 40.157B 39.76B 36.528B 35.088B 31.168B
Net profit -3.595B -2.546B -2.942B 4.166B 1.022B — — 1.711B — — — 3.443B 3.186B 2.496B 2.472B 1.31B 1.359B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Share price 37.01 19.31 33.63 48.33 47 48.16 72.81 60.56 104 99.13 115.8 113 101.95 71.89 49.4 55.3 55.96
Price performance 12m 0.92 -0.43 -0.3 0.03 -0.02 -0.34 0.2 -0.42 0.05 -0.14 0.02 0.11 0.42 0.46 -0.11 -0.01 —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

News

| Share on: X | Share on: Facebook | Share on: LinkedIn |

Latest news

Oct

26,

2026

Asundexian first Factor XIa inhibitor approved in China for stroke risk reduction after priority review

Oct

24,

2026

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

Oct

22,

2026

Finerenone showed consistent effects in reduction of UPCR, UACR and kidney function decline versus placebo in diverse patient populations with chronic kidney disease without diabetes

Oct

22,

2026

AskBio Announces 5 Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress

Oct

15,

2026

EU and UK Risk Falling Further Behind Global Agricultural Competitors, Weakening Strategic Autonomy

Oct

15,

2026

Vividion Therapeutics Expands Clinical Development of WRN Inhibitor VVD-214 with Phase II Combination Study in First-Line Patients with Advanced Colorectal Cancer

Overview

News

Speeches

Visual Assets opens in new window

Events opens in new window

Media Contacts opens in new window

Back to Newsroom

Important notice

This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities. There will be no public offer of the securities in any jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. An investment decision regarding the securities referred to herein should only be made on the basis of the securities prospectus.

This announcement is an advertisement and does not, under any circumstances, constitute a public offering or an invitation to the public in connection with any offer within the meaning of Regulation (EU) 2017/1129. The final prospectus, when published, will be available on the website of the Luxembourg Stock Exchange (www.luxse.com).

The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons.

The tender offer referenced herein is not being made, directly or indirectly, in or into the United States by use of the mails or by any means or instrumentality (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of any facility of a national securities exchange of the United States and the tender offer cannot be accepted by any such use, means, instrumentality or facility or from within the United States.

Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.

If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

Basis of access

Access to electronic versions of these materials is being made available on this webpage by Bayer in good faith and for information purposes only. Making press announcements and other documents available in electronic format on this webpage does not constitute an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Further, it does not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Bayer.

Confirmation of understanding and acceptance of disclaimer

By clicking on the “I AGREE” button, I certify that I am not located in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is prohibited or restricted.

I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the “I AGREE” button, I confirm that I am permitted to proceed to electronic versions of these materials.

Back to Newsroom

Please confirm your location here:

Choose country

  • Australia

  • Japan

  • Canada

  • South Africa

  • USA

  • Other

Disclaimer – Important

The following materials are not directed at or to be accessed by persons located in the United States, Australia, Canada or Japan. These materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States, Australia, Canada or Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any person to whom it is unlawful to make such offer or solicitation.

The securities mentioned herein have not been, and will not be, registered under the Securities Act and may not be offered or sold in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will be no public offer of the securities in the United States.

In the United Kingdom the following materials are only directed at (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (ii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on the materials or any of their contents.

In relation to each member state of the European Economic Area which has implemented the Directive 2003/71/EC, and any amendments thereto (the “Prospectus Directive”)(each a “Relevant Member State”), an offer to the public of the securities has not been made and will not be made in such Relevant Member State, except that an offer to the public in such Relevant Member State of any securities may be made at any time under the following exemptions from the Prospectus Directive, if they have been implemented in the Relevant Member State:

  • to any legal entity which is a qualified investor as defined in the Prospectus Directive,

  • to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, or

  • in any other circumstances falling within Article 3(2) of the Prospectus Directive;

provided that no such offer shall result in a requirement to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive.

For the purposes of this provision, the expression an “offer to the public” in relation to any securities in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase any securities, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State, and the expression “Prospectus Directive” includes any relevant implementing measure in each Relevant Member State.

Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.

If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

Basis of access

Access to electronic versions of these materials is being made available on this webpage by Bayer in good faith and for information purposes only. Making press announcements and other documents available in electronic format on this webpage does not constitute an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Further, it does not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Bayer.

Confirmation of understanding and acceptance of disclaimer

By clicking on the “I AGREE” button, I certify that I am not located in the United States, Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or restricted.

I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the “I AGREE” button, I confirm that I am permitted to proceed to electronic versions of these materials.

Back to Newsroom

Please confirm your location here:

Choose country

  • Australia

  • Japan

  • Canada

  • South Africa

  • USA

  • Other

Important Notice

This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities. There will be no public offer of the securities in any jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. An investment decision regarding the securities referred to herein should only be made on the basis of the securities prospectus.

This announcement is an advertisement and does not, under any circumstances, constitute a public offering or an invitation to the public in connection with any offer within the meaning of Regulation (EU) 2017/1129. The final prospectus, when published, will be available on the website of the Luxembourg Stock Exchange (www.luxse.com).

The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons.

The tender offer referenced herein is not being made, directly or indirectly, in or into the United States by use of the mails or by any means or instrumentality (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of any facility of a national securities exchange of the United States and the tender offer cannot be accepted by any such use, means, instrumentality or facility or from within the United States.

Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.

If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

Basis of access

Access to electronic versions of these materials is being made available on this webpage by Bayer in good faith and for information purposes only. Making press announcements and other documents available in electronic format on this webpage does not constitute an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Further, it does not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Bayer.

Confirmation of understanding and acceptance of disclaimer

By clicking on the “I AGREE” button, I certify that I am not located in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is prohibited or restricted.

I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the “I AGREE” button, I confirm that I am permitted to proceed to electronic versions of these materials.

Back to Newsroom

Important notice

This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities. There will be no public offer of the securities in any jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. An investment decision regarding the securities referred to herein should only be made on the basis of the securities prospectus.

This announcement is an advertisement and does not, under any circumstances, constitute a public offering or an invitation to the public in connection with any offer within the meaning of Regulation (EU) 2017/1129. The final prospectus, when published, will be available on the website of the Luxembourg Stock Exchange (www.luxse.com).

The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons.

The tender offer referenced herein is not being made, directly or indirectly, in or into the United States by use of the mails or by any means or instrumentality (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of any facility of a national securities exchange of the United States and the tender offer cannot be accepted by any such use, means, instrumentality or facility or from within the United States.

Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.

If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

Basis of access

Access to electronic versions of these materials is being made available on this webpage by Bayer in good faith and for information purposes only. Making press announcements and other documents available in electronic format on this webpage does not constitute an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Further, it does not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Bayer.

Confirmation of understanding and acceptance of disclaimer

By clicking on the “I AGREE” button, I certify that I am not located in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is prohibited or restricted.

I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the “I AGREE” button, I confirm that I am permitted to proceed to electronic versions of these materials.

Back to Newsroom

Please confirm your location here:

Choose country

  • Australia

  • Japan

  • Canada

  • South Africa

  • USA

  • Other

Important Notice

This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities. There will be no public offer of the securities in any jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction.

The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold in the United States or to, or for the benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements under the U.S. Securities Act.

Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.

If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

Basis of access

Access to electronic versions of these materials is being made available on this webpage by Bayer in good faith and for information purposes only. Making press announcements and other documents available in electronic format on this webpage does not constitute an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Further, it does not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Bayer.

Confirmation of understanding and acceptance of disclaimer

By clicking on the “I AGREE” button, I certify that I am not located in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is prohibited or restricted.

I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the “I AGREE” button, I confirm that I am permitted to proceed to electronic versions of these materials.

Back to Newsroom

Please confirm your location here:

Choose country

  • Australia

  • Japan

  • Canada

  • South Africa

  • USA

  • Other

Important Notice

This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities. There will be no public offer of the securities in any jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. An investment decision regarding the securities referred to herein should only be made on the basis of the securities prospectus.

This announcement is an advertisement and does not, under any circumstances, constitute a public offering or an invitation to the public in connection with any offer within the meaning of Regulation (EU) 2017/1129. The final prospectus, when published, will be available on the website of the Luxembourg Stock Exchange (www.luxse.com).

The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons.

Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.

If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

Basis of access

Access to electronic versions of these materials is being made available on this webpage by Bayer in good faith and for information purposes only. Making press announcements and other documents available in electronic format on this webpage does not constitute an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Further, it does not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Bayer.

Confirmation of understanding and acceptance of disclaimer

By clicking on the "I AGREE" button, I certify that I am not located in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is prohibited or restricted.

I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the "I AGREE" button, I confirm that I am permitted to proceed to electronic versions of these materials.

Back to Newsroom

Disclaimer

This website is intended to provide information to an international audience outside the USA and UK. Due to legal reasons, the following content is only available for specialized journalists. To access these pages, please confirm that you are a medical journalist and that you would like to accredit to the Bayer press portal.

Back to Newsroom

Disclaimer

This website is intended to provide information to an international audience outside the UK. Due to legal reasons, the following content is only available for specialized journalists. To access these pages, please confirm that you are a medical journalist and that you would like to accredit to the Bayer press portal.

Business & FinanceExport-IRExport-LatestNewsExport-TopNewsInvestor NewsBayer

October

30,

2026

|

02:02 AM

Europe/Amsterdam

Monsanto unanimously wins first Roundup™ trial since U.S. Supreme Court decision

Summary

Missouri verdict demonstrates that plaintiffs could not prove their claims following the U.S. Supreme Court’s landmark decision in Durnell

[Post this release on X](https://x.com/intent/post?text=Monsanto unanimously wins first Roundup™ trial since U.S. Supreme Court decision&url=https%3A%2F%2Fwww.bayer.com%2Fmedia%2Fen-us%2Fmonsanto-unanimously-wins-first-roundup-trial-since-us-supreme-court-decision%2F)

';

St. Louis, October 29, 2026 –A Missouri Circuit Court jury today reached a unanimous defense verdict in favor of Monsanto in the three-plaintiff case of Theresa Aretino, et al. v. Monsanto Company, the first Roundup™ trial to take place since the U.S. Supreme Court’s landmark ruling in Monsanto v. Durnell. The jury found for Monsanto on the design defect, fraud and negligence claims that each of the three plaintiffs pursued at trial following the Supreme Court’s favorable decision in Durnell, which preempted their failure-to-warn claims.

“We are pleased with the jury’s favorable verdict for Monsanto validating our belief that there is no evidence to prove design defect, fraud or negligence claims in the Roundup™ litigation,” said Bill Dodero, U.S. General Counsel and Global Head of Litigation. “This verdict should send a strong signal that plaintiffs who wish to pursue claims in the court system following the Durnell ruling will face significant challenges both in demonstrating they have viable claims and putting forth the necessary evidence to prove them in court.”

The first trial following****Durnell

In June 2026, the U.S. Supreme Court issued a landmark ruling in the Durnell Roundup™ case, affirming that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) expressly preempts state law claims based on failure-to-warn theories when the Environmental Protection Agency (EPA) has made a definitive determination on product safety. These claims have been a central theory in the Roundup™ litigation to date. With failure-to-warn claims no longer available, the Aretino plaintiffs pursued design defect and negligence claims. The verdict marks the first time a court has tested the sufficiency of evidence to support design defect and negligence claims at trial in the post-Durnell landscape.

Glyphosate’s safety

Glyphosate remains one of the most studied agricultural tools in history. The overwhelming weight of scientific evidence and the consensus of regulatory bodies and their scientific assessments worldwide support the safety of glyphosate-based herbicides when used as directed. The U.S. EPA has repeatedly and unequivocally determined that glyphosate is not likely to be carcinogenic and has consistently approved Roundup™ labels that contain no cancer warnings.

The company will continue to back the safety of its glyphosate-based herbicides – critical tools that farmers rely on to produce affordable food and feed the world – and will vigorously defend its products in any remaining litigation.

Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conformthem to future events or developments.

Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.

Contacts

| Brian Leake | Brian Leake [email protected] +1 314 370 3285 |

| Philipp Blank | Philipp Blank Law, Patents and Compliance, Information Technology and Digitalization [email protected] +49 214 30-20499 |

| Contact for investor inquiries: Bayer Investor Relations Team | Contact for investor inquiries: Bayer Investor Relations Team [email protected] +49 214 30-72704 |

| Erica Mulligan Contact for U.S. investor inquiries [email protected] +1 314-985-7457 |

Downloads

Newsroom

Sign up for our Newsletter

We will keep you informed about the latest news.

Sign up

PreviousNext

Company Logo

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer. More information

Allow All

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. Of course, you may use our Website without any cookies being set. In your browser, you can at any time configure or completely deactivate the use of cookies. This may, however, lead to a restriction of the functions or have adverse effects on the user-friendliness of our Website.

Cookies Details

Analytics Cookies

Analytics Cookies

Analytical Cookies will help us to analyze your use of and improve the performance of our Website and communications. For example, our promotional communications may include these cookies to measure performance and deliver more relevant offers/content based on preferences. If you do not allow these cookies we will not know when you have visited our Website, and will not be able to monitor its performance.

Cookies Details

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalization, including the services you have asked for. They may be set by us or by third-party providers whose services we have added to our pages. The information collected is not used to track your browsing activities on non-affiliated websites. If you do not allow these cookies then some or all of these services may not function properly.

Cookies Details

Sharing and Targeted Advertising

Sharing and Targeted Advertising

We and our partner will use this information to better tailor our content and advertisements to you and your interests, including to limit the number of times you are shown the same advertisement, to evaluate the efficiency of promotional campaigns, and to better comprehend the behavior of visitors after they have looked at a certain ad. Third parties may collect this information over time and combine it with information collected on different websites and online services across your devices. When you visit another website of the Advertisement Network, customized pop-ups tailored to your interests can be presented to you on the basis of the information collected on our Website. To opt out of the sharing of your personal information collected through cookies, move the toggle to the left and select "Save Settings". If you choose to opt out of this data sharing, you will still see ads, though they may be less relevant to you. These ads may be based on historical information or information shared or sold by other sources. You will need to renew this choice each time you clear your cookies or use a new browser or device. This opt-out applies only to certain cookie (“online”) data we have about you.

Cookies Details

Cookie List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject All

Powered by Onetrust

Prompts

Bayer Aktiengesellschaft (ticker BAYN), listed in Germany.

ETFs Holding Bayer Aktiengesellschaft

ETF Weight in ETF Shares Market value As of
IMOM 2.07% 44,466 $ 2.75M Nov 18, 2026
AIVI 1.68% 17,768 $ 983.408K Jun 30, 2026
DTAN 1.64% 5,780 $ 357.166K Nov 17, 2026
DFIV 1.14% 4,081,515 $ 255.47M Nov 12, 2026
CGGO 0.73% 1,357,020 $ 85.054M Nov 16, 2026
SEIE 0.66% 136,840 $ 7.574M Jun 30, 2026
DXIV 0.52% 20,004 $ 1.252M Nov 12, 2026
RCGE 0.52% 8,366 $ 520K Nov 18, 2026
RFDI 0.49% 14,521 $ 804.592K Jul 31, 2026
AVSD 0.46% 27,281 $ 1.699M Nov 16, 2026
RAAX 0.42% 104,885 $ 5.679M Sep 30, 2026
DFIC 0.42% 1,038,402 $ 64.996M Nov 12, 2026
IVSI 0.39% 555 $ 30.699K Jun 30, 2026
RINT 0.34% 8,466 $ 468.282K Jun 30, 2026
DFAI 0.32% 942,436 $ 58.989M Nov 12, 2026
DFAX 0.29% 551,063 $ 34.492M Nov 12, 2026
QUIZ 0.25% 4,121 $ 234.802K Aug 31, 2026
NTSI 0.24% 21,132 $ 1.17M Jun 30, 2026
DIHP 0.23% 240,009 $ 15.023M Nov 12, 2026
GEW 0.20% 5,174 $ 294.723K Aug 31, 2026
AVDE 0.20% 624,510 $ 38.9M Nov 16, 2026
BRIE 0.20% 17,179 $ 978.557K Aug 31, 2026
FENI 0.18% 338,571 $ 18.727M Jun 30, 2026
TIER 0.15% 925 $ 51.334K Jul 31, 2026